You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and clinical assessment of a robust, 3D printed titanium, myoelectric powered prosthetic digit system

    SBC: POINT DESIGNS, LLC            Topic: 106

    ABSTRACT Approximately 600,000 people live with partial hand amputations in the United States, with an estimated 14,500 new cases occurring each year. Despite the advances in miniaturized electronics and motors, there has been very little advancement in mechatronic prosthetic digits for this underserved patient population. In fact, to date, there is only one myoelectric prosthetic option for patie ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

    SBC: EXAVIR THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Comparative testing of tatCN19o for neuroprotection in rodent tMCAo

    SBC: NEUREXIS THERAPEUTICS, INC.            Topic: NINDS

    Project Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we w ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. An Interactive Education Program to Reduce High Risk Behavior in Adolescents

    SBC: KLEIN BUENDEL, INC.            Topic: NICHD

    Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients

    SBC: Allander Biotechnologies            Topic: NIDCR

    Summary Oral mucositis, a severe oral ulceration, is a common toxic effect of radio- or chemoradio-therapy (RT or CRT) and a limiting factor to using the optimal dose of radiation for effective cancer treatment. Intensity modulated RT (IMRT) and stereotactic Body RT (SBRT) spare more normal tissues and lessen chronic side effects, but not oral mucosa in head and neck cancer patients. To date, Pali ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a

    SBC: CERIA THERAPEUTICS INC            Topic: NHLBI

    SUMMARYAcute respiratory distress syndrome (ARDS) accounts for 10% of ICU admissions worldwide, with a mortality as high as 46%. ARDS incidence has risen dramatically during the COVID-19 pandemic. Despite improvements in critical care and early detection of lung injury, the management of ARDS remains largely supportive. Although mechanical ventilation may provide the necessary life support, impair ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. The Point Powered: A Robust Actuated Prosthetic Finger for Partial Hand Amputation

    SBC: POINT DESIGNS, LLC            Topic: NIBIB

    ABSTRACT Approximately 600,000 people live with partial hand limb loss (PHLL) in the United States, with an estimated 14,500 new cases occurring each year. Despite the advances in miniaturized electronics and motors, there has been very little advancement in mechatronic prosthetic digits for this underserved patient population. In fact, to date, there is only one myoelectric prosthetic option for ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical evaluation of an otoprotectant TT002

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    Project Summary Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However, cisplatin therapy causes hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection from cisplatin-induced hearing loss (CIHL). Most candid ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Filtration Media for In-Home PFAS Removal from Drinking Water

    SBC: TDA RESEARCH, INC.            Topic: NIEHS

    Project Summary/Abstract Title Filtration Media for In-Home PFAS Removal from Drinking Water SBIR Phase II Application P.I.: Steven Dietz, TDA Research, Inc. Per- and polyfluoroalkyl substances (PFAS), also commonly known as perfluorinated compounds, are a large family of man-made, globally distributed chemicals that have been used for decades. Perfluorooctanoic acid (PFOA) and perfluorooctane sul ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. VDX-111: A novel targeted therapeutic for triple-negative breast cancer

    SBC: VONA THERAPEUTICS LLC            Topic: 102

    PROJECT SUMMARY Triple-negative breast cancers (TNBC) represent a significant challenge to basic scientists studying themolecular underpinnings of the disease and to patients and clinicians who deal directly with this most deadly andtherapy-resistant of breast cancers. Presently, targeted approaches toward the treatment of TNBC are lacking.This project directly addresses this critical unmet need. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government